Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660834 | 0.98 | TAAR1 (0.52) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL5370837 | 0.89 | MAPK1 (0.47) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL1554318 | 0.87 | HRH1 (0.46) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL1555851 | 0.85 | TDP1 (0.41) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL1555826 | 0.83 | IDO1 (0.47) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL93572 | 0.80 | TAAR1 (0.50) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL5377192 | 0.80 | MAOB (0.40) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL5377333 | 0.80 | MAOB (0.39) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL1554330 | 0.80 | AGXT (0.50) | TAAR1KDM4EMAPK1MEN1TRPM2 | |
| SCHEMBL28466216 | 0.79 | KDM4E (0.58) | TAAR1KDM4EMAPK1MEN1TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056896-A | Application of 2-aminoethoxy diphenyl borate in preparation of medicine for preventing and/or treating gout | 安徽医科大学第二附属医院 | 2026-05-19 | — | — | CN | claimed |
| CN-112782328-B | Method for detecting catecholamine and metabolites thereof in urine, kit and application of kit | 深圳华大医学检验实验室 | 2024-07-09 | — | — | CN | claimed |
| CN-117285917-A | Double-base cross-linked zwitterionic weak gel oil displacement system and preparation method thereof | 北京麒瑞鸿基石油科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-116981449-A | Compounds and compositions for inducing neuroprotection | 瑞斯特医疗公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4142703-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-03-08 | — | — | EP | claimed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114950459-A | Hydrogenation catalyst carrier and preparation method thereof, hydrogenation catalyst and preparation method thereof | 中国石油天然气股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | claimed |
| CN-112782328-A | Method and kit for detecting catecholamine and metabolites thereof in urine and application of kit | 深圳华大临床检验中心 | 2021-05-11 | — | — | CN | claimed |
| CN-111904967-A | Application of 2-APB in preparation of medicine for treating non-alcoholic steatohepatitis | 重庆医科大学 | 2020-11-10 | — | — | CN | claimed |
| CN-107583053-B | Endoplasmic reticulum Ca2+Application of blocking agent in preparation of medicine for treating bone arsenic poisoning | 姜玉峰 | 2020-09-25 | — | — | CN | claimed |
| US-8575106-B2 | Cosmetic uses of modified stressed yeast extracts and related compositions | AVON PRODUCTS, INC. (US) | 2013-11-05 | — | — | US | claimed |
| CN-103037886-A | Cosmetic use of extracts of modified stressed yeasts and related compositions | AVON PROD INC | 2013-04-10 | — | — | CN | claimed |
| EP-2473183-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | Avon Products, Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| US-7960129-B2 | Assays and methods for determining STIM2 activity | THE QUEEN'S MEDICAL CENTER (US) | 2011-06-14 | — | — | US | claimed |
| US-20110052517-A1 | Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions | Avon Place (US) | 2011-03-03 | — | — | US | claimed |
| WO-2011025635-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PRODUCTS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-20080038365-A1 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2008-02-14 | — | — | US | claimed |
| US-20060257500-A1 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2006-11-16 | — | — | US | claimed |
| CN-122056896-A | Application of 2-aminoethoxy diphenyl borate in preparation of medicine for preventing and/or treating gout | 安徽医科大学第二附属医院 | 2026-05-19 | — | — | CN | disclosed |
| CN-122056896-A | Application of 2-aminoethoxy diphenyl borate in preparation of medicine for preventing and/or treating gout | 安徽医科大学第二附属医院 | 2026-05-19 | — | — | CN | disclosed |
| CN-122056896-A | Application of 2-aminoethoxy diphenyl borate in preparation of medicine for preventing and/or treating gout | 安徽医科大学第二附属医院 | 2026-05-19 | — | — | CN | disclosed |
| US-20260124270-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | DOMPE FARM SPA (IT) | 2026-05-07 | — | — | US | disclosed |
| US-12558399-B2 | Isocyclosporin A for topical treatment of ocular diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| CN-121221617-A | Application of 2-amino ethoxy diphenyl borate in preparing medicine for improving endometrial receptivity | 中国医科大学附属盛京医院 | 2025-12-30 | — | — | CN | disclosed |
| EP-4559529-A2 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | Dompé farmaceutici S.p.A. (IT) | 2025-05-28 | — | — | EP | disclosed |
| CN-117016600-B | Gallic acid-mediated photodynamic antibacterial fresh-keeping liquid and fresh-keeping method thereof | 广西民族大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4329725-B1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | DOMPE FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| CN-119816492-A | TRPV2 channel blocker and use thereof | 伊契洛夫科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119630639-A | Haloalkane, alkylating agent using same, and method for producing nucleoside derivative | 东丽株式会社 | 2025-03-14 | — | — | CN | disclosed |
| US-20250082719-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | DOMPE' FARMACEUTICI S.P.A. (IT) | 2025-03-13 | — | — | US | disclosed |
| CN-119403563-A | Therapeutic agents and methods | 剑桥企业有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119199000-A | Thin-layer identification of micro-emulsion for evaluating multiple particles of dyspnea Zu Pa | 新疆医科大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-119118953-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-114269556-B | Composition, film, near infrared cut filter, pattern forming method, laminate, solid-state imaging element, infrared sensor, image display device, camera module, and compound | 富士胶片株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-113166186-B | Stable vaccine against clostridium difficile | 爱杜西亚药品有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240349724-A1 | ANTIMICROBIAL COMPOSITIONS EFFECTIVE AGAINST BACTERIA AND FUNGUS | TerMir Inc. | 2024-10-24 | — | — | US | disclosed |
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115279731-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12059003-B2 | Antimicrobial compositions effective against bacteria and fungus | TerMir Inc. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112782328-B | Method for detecting catecholamine and metabolites thereof in urine, kit and application of kit | 深圳华大医学检验实验室 | 2024-07-09 | — | — | CN | disclosed |
| EP-3989979-B1 | CAPACITATIVE CALCIUM ENTRY INHIBITORS | UNIV PARIS SACLAY (FR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103389-A | Fluorescent sensor for monitoring calcium kinetics | J·杨 | 2024-05-28 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-115267039-B | Thin layer chromatography identification method for distinguishing field horsetail from canine field horsetail | 陕西嘉禾生物科技股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4329725-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | Dompé Farmaceutici S.p.A. (IT) | 2024-03-06 | — | — | EP | disclosed |
| CN-117099188-A | Substrate processing method and substrate processing apparatus | 东京毅力科创株式会社 | 2023-11-21 | — | — | CN | disclosed |
| CN-117016600-A | Gallic acid-mediated photodynamic antibacterial fresh-keeping liquid and fresh-keeping method thereof | 广西民族大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-116981449-A | Compounds and compositions for inducing neuroprotection | 瑞斯特医疗公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-113826502-B | Method for improving flavonoid content in camellia oleifera seeds | 中南林业科技大学 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116854693-A | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115728409-B | Qualitative and quantitative detection method for Xiasangju particles | 广州白云山星群(药业)股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023118487-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | ISOXA S.R.L. (IT) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201398-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | Isoxa S.r.l. (IT) | 2023-06-28 | — | — | EP | disclosed |
| CN-109996546-B | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116173047-A | Use of 2-APB for the treatment of diseases caused by clostridium perfringens Epsilon toxin | 中国人民解放军军事科学院军事医学研究院 | 2023-05-30 | — | — | CN | disclosed |
| CN-115996715-A | Treatment of viral conjunctivitis | 奥可金公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | disclosed |
| CN-113906945-B | Method for promoting accumulation of flavonoid content in camellia oleifera seeds | 中南林业科技大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-115969862-A | Application of 2-aminoethyl dibenzoborate in preparation of medicines for treating leucocythemia | 深圳市第二人民医院(深圳市转化医学研究院) | 2023-04-18 | — | — | CN | disclosed |
| CN-115835878-A | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | 钙医学公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4121089-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | Calcimedica, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4118070-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022220147-A1 | MUSCLE ATROPHY INHIBITION COMPOSITION | 国立大学法人神戸大学 | 2022-10-20 | — | — | WO | disclosed |
| WO-2022211057-A1 | SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING DEVICE | 東京エレクトロン株式会社 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022191044-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, INFRARED SENSOR, CAMERA MODULE, COMPOUND, AND INFRARED ABSORBING AGENT | 富士フイルム株式会社 | 2022-09-15 | — | — | WO | disclosed |
| EP-4055018-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054559-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-114950459-A | Hydrogenation catalyst carrier and preparation method thereof, hydrogenation catalyst and preparation method thereof | 中国石油天然气股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-108957953-B | Curable composition, cured film, near-infrared cut filter, camera module, and methods for producing these | 富士胶片株式会社 | 2022-08-23 | — | — | CN | disclosed |
| WO-2022148710-A1 | AGENTS FOR IMPROVING WATER USE EFFICIENCY | SHANDONG UNIVERSITY (CN) | 2022-07-14 | — | — | WO | disclosed |
| CN-111388485-B | Application of 2-APB in preparation of osteoarthritis treatment drug | 安徽医科大学第二附属医院 | 2022-05-24 | — | — | CN | disclosed |
| CN-111388485-B | Application of 2-APB in preparation of osteoarthritis treatment drug | 安徽医科大学第二附属医院 | 2022-05-24 | — | — | CN | disclosed |
| CN-109897107-B | Nano antibody and preparation method thereof | 深圳华大生命科学研究院 | 2022-05-17 | — | — | CN | disclosed |
| EP-3989979-A1 | CAPACITATIVE CALCIUM ENTRY INHIBITORS | Université Paris-Saclay (FR) | 2022-05-04 | — | — | EP | disclosed |
| CN-114269556-A | Composition, film, near-infrared cut filter, pattern formation method, laminate, solid-state imaging element, infrared sensor, image display device, camera module, and compound | 富士胶片株式会社 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022065215-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING SENSOR, IMAGE DISPLAY DEVICE, INFRARED SENSOR, CAMERA MODULE, COMPOUND, AND INFRARED ABSORBER | 富士フイルム株式会社 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | disclosed |
| EP-3937945-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113721316-A | Composition, film, near-infrared cut filter, laminate, and pattern formation method | 富士胶片株式会社 | 2021-11-30 | — | — | CN | disclosed |
| CN-110352221-B | Composition, film, infrared cut filter, solid-state imaging element, infrared sensor, camera module, and novel compound | 富士胶片株式会社 | 2021-11-09 | — | — | CN | disclosed |
| CN-112426425-B | Use of citrusinine-II for the preparation of agents affecting the perception of itch and pain in humans and animals | 中国科学院昆明动物研究所 | 2021-10-29 | — | — | CN | disclosed |
| CN-113546086-A | Application of 2-APB in preparation of medicine for promoting skin wound healing | 安徽医科大学第二附属医院 | 2021-10-26 | — | — | CN | disclosed |
| CN-105683389-B | Method for specifically labeling live bacteria comprising use of modified monosaccharide compounds | 国家科学研究中心 | 2021-09-28 | — | — | CN | disclosed |
| CN-102164594-B | Use of anti-connexin agents for modulating the efficacy of psychotropic drug molecules | 原子能和替代能源委员会 | 2021-09-28 | — | — | CN | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-108474884-B | Composition, film, near-infrared cut filter, and laminate | 富士胶片株式会社 | 2021-09-17 | — | — | CN | disclosed |
| WO-2021183639-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
| CN-107847754-B | System and method for applying pulsed electromagnetic fields | 新加坡国立大学 | 2021-09-10 | — | — | CN | disclosed |
| US-11077080-B2 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs | COMMISSARIAT A L'ENERGIE ATOMIQUE AUX ENERGIES ALTERNATIVES (FR) | 2021-08-03 | — | — | US | disclosed |
| CN-113166186-A | Stable vaccine against clostridium difficile | 爱杜西亚药品有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11035003-B2 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110144046-B | Boron-containing phenolic resin microspheres and preparation method of carbon microspheres | 沙县宏盛塑料有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112782328-A | Method and kit for detecting catecholamine and metabolites thereof in urine and application of kit | 深圳华大临床检验中心 | 2021-05-11 | — | — | CN | disclosed |
| CN-110951613-B | Single cell array chip and method for screening ion channel medicine | 北京大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-112426425-A | Use of citrusinine-II for the preparation of agents affecting the perception of itch and pain in humans and animals | 中国科学院昆明动物研究所 | 2021-03-02 | — | — | CN | disclosed |
| CN-109415573-B | Composition, film, filter, laminate, solid-state imaging element, image display device, infrared sensor, and compound | 富士胶片株式会社 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020260840-A1 | CAPACITATIVE CALCIUM ENTRY INHIBITORS | UNIVERSITÉ PARIS-SACLAY (FR) | 2020-12-30 | — | — | WO | disclosed |
| CN-111904967-A | Application of 2-APB in preparation of medicine for treating non-alcoholic steatohepatitis | 重庆医科大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-111904967-A | Application of 2-APB in preparation of medicine for treating non-alcoholic steatohepatitis | 重庆医科大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-107583053-B | Endoplasmic reticulum Ca2+Application of blocking agent in preparation of medicine for treating bone arsenic poisoning | 姜玉峰 | 2020-09-25 | — | — | CN | disclosed |
| CN-107583053-B | Endoplasmic reticulum Ca2+Application of blocking agent in preparation of medicine for treating bone arsenic poisoning | 姜玉峰 | 2020-09-25 | — | — | CN | disclosed |
| WO-2020185881-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10765670-B2 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-09-08 | — | — | US | disclosed |
| CN-111388485-A | Application of 2-APB in preparation of osteoarthritis treatment drug | 安徽医科大学第二附属医院 | 2020-07-10 | — | — | CN | disclosed |
| CN-111388485-A | Application of 2-APB in preparation of osteoarthritis treatment drug | 安徽医科大学第二附属医院 | 2020-07-10 | — | — | CN | disclosed |
| EP-3651748-A1 | ANTIMICROBIAL COMPOSITIONS EFFECTIVE AGAINST BACTERIA AND FUNGUS | Termir, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-111093643-A | Antimicrobial compositions effective against bacteria and fungi | 特米尔有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-110951613-A | Single cell array chip and method for screening ion channel medicine | 北京大学 | 2020-04-03 | — | — | CN | disclosed |
| WO-2020051701-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019241348-A9 | AMPHIPHILIC AMINOGLYCOSIDE CONNEXIN HEMICHANNEL INHIBITORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-02-27 | — | — | WO | disclosed |
| US-10337068-B2 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190160848-A1 | CURABLE COMPOSITION, LITHOGRAPHIC PRINTING PLATE PRECURSOR, AND METHOD FOR PRODUCING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-3489025-A1 | CURABLE COMPOSITION, ORIGINAL PLATE FOR LITHOGRAPHIC PRINTING PLATES, AND METHOD FOR MANUFACTURING LITHOGRAPHIC PRINTING PLATE | FUJIFILM Corporation (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10240157-B2 | Diagnostic and screening methods for atopic dermatitis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2019014424-A1 | ANTIMICROBIAL COMPOSITIONS EFFECTIVE AGAINST BACTERIA AND FUNGUS | TERMIR, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-2773337-B1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20180194821-A1 | REGULATORS OF NFAT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
| EP-2157979-B1 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | CALCIMEDICA INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20180177773-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-06-28 | — | — | US | disclosed |
| EP-2473183-B1 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PROD INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180147206-A1 | ACTIVATION OF NEURONAL STORE-OPERATED CALCIUM ENTRY PATHWAY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180100155-A1 | DIAGNOSTIC AND SCREENING METHODS FOR ATOPIC DERMATITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-12 | — | — | US | disclosed |
| US-9932378-B2 | Regulators of NFAT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180024146-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | WEST VIRGINIA UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-9797913-B2 | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) | Blanchette Rockefeller Neuroscienses Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9790506-B2 | Diagnostic and screening methods for atopic dermatitis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-17 | — | — | US | disclosed |
| WO-2017077401-A1 | METHOD FOR THE ULTRA-SENSITIVE DETERMINATION OF CATECHOLAMINES AND THEIR METABOLITES | PHARMASAN LABS, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-2368912-B1 | Regulators of NFAT | CHILDREN'S MEDICAL CENTER CORP (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3004336-B1 | ENZYMES CATALYZING THE GLYCOSYLATION OF POLYPHENOLS | UNIVERSITÄT HAMBURG (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-20160376655-A1 | TRPC6 INVOLVED IN GLOMERULONEPHRITIS | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2016182812-A1 | ACTIVATION OF NEURONAL STORE-OPERATED CALCIUM ENTRY PATHWAY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160305961-A1 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | WEST VIRGINIA UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-2890359-B1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | AVON PROD INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2135076-B1 | FUNCTIONAL IDENTIFICATION OF PROTEINS UNDERLYING ICRAC ACTIVITY IN A CELL | QUEENS MEDICAL CT (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2135077-B1 | ASSAYS AND METHODS FOR DETERMINING STIM2 ACTIVITY | QUEENS MEDICAL CT (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9433642-B2 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2322934-B1 | A Kit for diagnosing the Alzheimer's disease | BRNI NEUROSCIENCES INST (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2339349-B1 | Methods for identifying Alzheimer's therapeutics | BRNI NEUROSCIENCES INST (US) | 2016-08-17 | — | — | EP | disclosed |
| CN-105778703-A | Interior wall coating | 青岛锦涟鑫商贸有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160169868-A9 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | CALCIMEDICA, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160090578-A1 | ENZYMES CATALYZING THE GLYCOSYLATION OF POLYPHENOLS | UNIVERSITAET HAMBURG (DE) | 2016-03-31 | — | — | US | disclosed |
| US-20160052981-A1 | REGULATORS OF NFAT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-9188595-B2 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | Blanchett Rockefeller Neurosciences Institute (US) | 2015-11-17 | — | — | US | disclosed |
| US-9163078-B2 | Regulators of NFAT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150272915-A1 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-10-01 | — | — | US | disclosed |
| US-9132145-B2 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NEW YORK UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2890359-A1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | Avon Products, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150184163-A1 | DIAGNOSTIC AND SCREENING METHODS FOR ATOPIC DERMATITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-02 | — | — | US | disclosed |
| US-9023327-B2 | DICKKOPF-1 expression modulating compositions and uses thereof | AVON PRODUCTS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-104298891-A | Virtual screening method for anti-inflammation and anti-rejection drugs taking CRAC channels as targets | UNIV SHANDONG | 2015-01-21 | — | — | CN | disclosed |
| US-20150011584-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-01-08 | — | — | US | disclosed |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2773337-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2014-09-10 | — | — | EP | disclosed |
| US-8828674-B2 | Functional identification of proteins underlying Icrac activity in a cell | THE QUEEN'S MEDICAL CENTER (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140187616-A1 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | STAUDERMAN KENNETH A (US) | 2014-07-03 | — | — | US | disclosed |
| CN-103906511-A | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | COMMISSARIAT ENERGIE ATOMIQUE | 2014-07-02 | — | — | CN | disclosed |
| US-20140065086-A1 | Dickkopf-1 Expression Modulating Compositions and Uses Thereof | AVON PRODUCTS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014035401-A1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | AVON PRODUCTS, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140031245-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2014-01-30 | — | — | US | disclosed |
| US-8574635-B2 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NEW YORK UNIVERSITY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575106-B2 | Cosmetic uses of modified stressed yeast extracts and related compositions | AVON PRODUCTS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8507269-B2 | Calcium channel proteins and uses thereof | CALCIMEDICA, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2013064579-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2013-05-10 | — | — | WO | disclosed |
| EP-2586436-A1 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2013-05-01 | — | — | EP | disclosed |
| EP-2344146-B1 | ANTI-CONNEXINE AGENTS FOR USE TO MODULATE THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2013-04-17 | — | — | EP | disclosed |
| CN-103037886-A | Cosmetic use of extracts of modified stressed yeasts and related compositions | AVON PROD INC | 2013-04-10 | — | — | CN | disclosed |
| US-8399185-B2 | Regulators of NFAT | IMMUNE DISEASE INSTITUTE, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2031398-B1 | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio as Alzheimer's disease-specific molecular biomarkers (ADSMB) | BRNI NEUROSCIENCES INST (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8362033-B1 | Compounds and methods to dysregulate CA2+ homeostasis for cancer treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130017198-A1 | MANIPULATION OF CALCIUM CHANNELS TO REGULATE AFTER-DEPOLARIZATION EVENTS IN CARDIAC MYOCYTES | THE UAB RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
| EP-1984400-B1 | REGULATORS OF NFAT | IMMUNE DISEASE INST INC (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2473183-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | Avon Products, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120135960-A2 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-05-31 | — | — | US | disclosed |
| US-20110281949-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE AND MODULATING TRANSIENT RECEPTOR POTENTIAL CHANNELS | MINKE BARUCH (IL) | 2011-11-17 | — | — | US | disclosed |
| US-20110269174-A1 | REGULATORS OF NFAT | IMMUNE DISEASE INSTITUTE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011119939-A2 | MANIPULATION OF CALCIUM CHANNELS TO REGULATE AFTER-DEPOLARIZATION EVENTS IN CARDIAC MYOCYTES | THE UAB RESEARCH FOUNDATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368912-A1 | Regulators of NFAT | Immune Disease Institute, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| CN-102164594-A | Use of anti-connexin agents for modulating the efficacy of psychotropic drug molecules | COMMISSARIAT ENERGIE ATOMIQUE | 2011-08-24 | — | — | CN | disclosed |
| EP-2344146-A1 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172188-A1 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | BIO MODELING SYSTEMS OU BMSYSTEMS (FR) | 2011-07-14 | — | — | US | disclosed |
| EP-2339349-A1 | Methods for identifying Alzheimer's therapeutics | Blanchette Rockefeller Neurosciences Institute (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110142973-A1 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NEW YORK UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-7960129-B2 | Assays and methods for determining STIM2 activity | THE QUEEN'S MEDICAL CENTER (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2322934-A1 | A Kit for diagnosing the Alzheimer's disease | Blanchette Rockefeller Neurosciences Institute (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322936-A1 | Methods for identifying a lead compound for treatment of Alzheimer's disease | Blanchette Rockefeller Neurosciences Institute (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2317321-A1 | Methods for monitoring Alzheimer's progression by measuring a biomarker | Blanchette Rockefeller Neurosciences Institute (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110052517-A1 | Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions | Avon Place (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2011025635-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PRODUCTS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110020810-A1 | TRPC6 INVOLVED IN GLOMERULONEPHRITIS | DUKE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2263090-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | Blanchette Rockefeller Neurosciences Institute (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100278803-A1 | Alzheimer's Disease Diagnosis Based on Mitogen-Activated Protein Kinase Phosphorylation | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2010-11-04 | — | — | US | disclosed |
| US-7745597-B2 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010029131-A9 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-7682807-B2 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2010029131-A1 | USE OF ANTI-CONNEXIN AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC DRUGS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-03-18 | — | — | WO | disclosed |
| EP-2157979-A1 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | Calcimedica, Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20100022646-A1 | METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS | TRIGEN LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2135076-A2 | FUNCTIONAL IDENTIFICATION OF PROTEINS UNDERLYING ICRAC ACTIVITY IN A CELL | The Queen's Medical Center (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135077-A1 | ASSAYS AND METHODS FOR DETERMINING STIM2 ACTIVITY | The Queen's Medical Center (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | QIN NING | 2009-11-05 | — | — | US | disclosed |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | QIN NING | 2009-11-05 | — | — | US | disclosed |
| WO-2009126232-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7595167-B2 | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2009-09-29 | — | — | US | disclosed |
| US-7575882-B2 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-7575882-B2 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20090178146-A1 | Regulators of NFAT | IMMUNE DISEASE INSTITUTE, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1934618-B1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | BRNI NEUROSCIENCES INST (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090061031-A1 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | disclosed |
| EP-2031398-A1 | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio as Alzheimer's disease-specific molecular biomarkers (ADSMB) | Blanchette Rockefeller Neurosciences Institute (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090053753-A1 | FUNCTIONAL IDENTIFICATION OF PROTEINS UNDERLYING Icrac ACTIVITY IN A CELL | THE QUEEN'S MEDICAL CENTER (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1549950-B1 | METHODS FOR IDENTIFYING GLUCOSE UPTAKE MODULATORS | BIOVITRUM AB PUBL (SE) | 2009-02-11 | — | — | EP | disclosed |
| US-20090029873-A1 | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2009-01-29 | — | — | US | disclosed |
| US-20090023177-A1 | ASSAYS AND METHODS FOR DETERMINING STIM2 ACTIVITY | THE QUEEN'S MEDICAL CENTER (US) | 2009-01-22 | — | — | US | disclosed |
| CN-101322032-A | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB) | BRNI NEUROSCIENCES INST (US) | 2008-12-10 | — | — | CN | disclosed |
| WO-2008148108-A1 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | CALCIMEDICA, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293092-A1 | CALCIUM CHANNEL PROTEINS AND USES THEREOF | CALCIMEDICA, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1984400-A2 | REGULATORS OF NFAT | Immune Disease Institute, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008118793-A2 | FUNCTIONAL IDENTIFICATION OF PROTEINS UNDERLYING ICRAC ACTIVITY IN A CELL | THE QUEEN'S MEDICAL CENTER (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118795-A1 | ASSAYS AND METHODS FOR DETERMINING STIM2 ACTIVITY | THE QUEEN'S MEDICAL CENTER (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080221042-A1 | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) | WEST VIRGINIA UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| EP-1934618-A2 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | Blanchette Rockefeller Neurosciences Institute (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1925315-A2 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | Blanchette Rockefeller Neurosciences Institute (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1385531-B1 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BRNI NEUROSCIENCES INST (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20080038365-A1 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039392-A1 | CRAC channel and modulator screening methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007139926-A2 | CRAC CHANNEL AND MODULATOR SCREENING METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007081804-A9 | REGULATORS OF NFAT | CBR INST FOR BIOMED RES INC (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007081804-A2 | REGULATORS OF NFAT | IMMUNE DISEASE INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070105086-A1 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105086-A1 | Compositions and methods for identifying modulators of TRPV2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007053526-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING MODULATORS OF TRPV2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047029-A2 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO AS ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007044094-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO AS ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007043998-A1 | ALZHEIMER’S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082366-A1 | Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2007-04-12 | — | — | US | disclosed |
| US-20060257500-A1 | TRPC6 involved in glomerulonephritis | DUKE UNIVERSITY (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060172920-A1 | Oxidised lipids as reversal agents for boronic acid drugs | TRIGEN LIMITED (GB) | 2006-08-03 | — | — | US | disclosed |
| US-20060172978-A1 | Method of neutralising organoboronates with acids | TRIGEN LIMITED (GB) | 2006-08-03 | — | — | US | disclosed |
| WO-2006059082-A1 | OXIDISED LIPIDS AS REVERSAL AGENTS FOR BORONIC ACID DRUGS | TRIGEN LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006059083-A1 | NEUTRALISING AGENTS FOR BORONIC ACID DRUGS | TRIGEN LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
| EP-1549950-A1 | METHODS FOR IDENTIFYING GLUCOSE UPTAKE MODULATORS | BIOVITRUM AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050059092-A1 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | BLANCHETTE ROCKEFELLER NEURSOCIENCES INSTITUTE (US) | 2005-03-17 | — | — | US | disclosed |
| US-20040092456-A1 | Methods for identifying glucose uptake modulators | HB KATZ RESEARCH AND EDUCATION (SE) | 2004-05-13 | — | — | US | disclosed |
| EP-1385531-A4 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BRNI NEUROSCIENCES INST (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1385531-A2 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | Blanchette Rockefeller Neurosciences Institute (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004001410-A1 | METHODS FOR IDENTIFYING GLUCOSE UPTAKE MODULATORS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-20030148259-A1 | Method of identifying insulin secretion stimulating compounds, and the use of such compounds in treating insulin-secretion related disorders | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | disclosed |
| WO-2003065036-A1 | METHOD OF IDENTIFYING INSULIN SECRETION STIMULATING COMPOUNDS, AND THE USE OF SUCH COMPOUNDS IN TREATING INSULIN-SECRETION RELATED DISORDERS | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | WO | disclosed |
| WO-2002067764-A3 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BRNI NEUROSCIENCES INST (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002067764-A2 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6420181-B1 | DETECTING PREFERENTIAL PARTICLE IN SOLUTION; OBTAIN SOLUTION CONTAINING PARTICLE, MIX WITH SOLVENT, INSERT INTO TUBE, INCUBATE WITH CHROMOGENIC DETECTION INDICATOR, MONITOR SAMPLE FOR SIGNAL | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2002-07-16 | — | — | US | disclosed |
| US-6403352-B1 | CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE NUCLEIC ACID; GENE EXPRESSION OF ANTISENSE CONSTRUCTS; GENETIC ENGINEERING | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| US-6362395-B1 | FOR INDUCTION OF MALE STERILITY; FOR HYBRID PLANT PRODUCTION, FOR REDUCING POLLEN PRODUCTION | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION | 2002-03-26 | — | — | US | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-0922095-A4 | COMPOSITIONS AND METHODS FOR PRODUCTION OF MALE-STERILE PLANTS | UNIV WASHINGTON (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6077991-A | NUCLEIC ACID SEQUENCES CODING A PROTEIN WITH CALCIUM/CALMODULIN KINASE ACTIVITY; FOR THE INDUCTION OF SEX PREFERENTIAL STERILITY IN PLANTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0922095-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF MALE-STERILE PLANTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1997035968-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF MALE-STERILE PLANTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0519496-B1 | Thermosetting copolymers, silicon carbide-based fiber and processes for producing same | TONEN CORP (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0404503-B1 | Boron-containing, silicon nitride-based ceramic shaped body production process | TONEN CORP (JP) | 1996-03-06 | — | — | EP | disclosed |
| EP-0389084-B1 | Process for producing a polyborosilazane | TONEN CORP (JP) | 1995-09-20 | — | — | EP | disclosed |
| US-5292830-A | Silane, silazane, boron block crosslinked copolymers | TONEN CORPORATION (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0519496-A1 | Thermosetting copolymers, silicon carbide-based fiber and processes for producing same | Tonen Corporation (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-5128286-A | BORON-CONTAINING, SILICON NITRIDE-BASED CERAMIC SHAPED BODY | TONEN CORPORATION (JP) | 1992-07-07 | — | — | US | disclosed |
| US-5030744-A | Polyborosilazane and process for producing same | TONEN CORPORATION (JP) | 1991-07-09 | — | — | US | disclosed |
| EP-0404503-A1 | Boron-containing, silicon nitride-based ceramic shaped body production process | Tonen Corporation (JP) | 1990-12-27 | — | — | EP | disclosed |
| EP-0389084-A2 | Process for producing a polyborosilazane | Tonen Corporation (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0389084-A2 | Process for producing a polyborosilazane | Tonen Corporation (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142973-A1 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | LPL, ADIPOR2, EBP | TAAR1 4529/4885KDM4E 4389/4885MAPK1 4215/4885 |
| US-20060172920-A1 | Oxidised lipids as reversal agents for boronic acid drugs | LIPC, APOB, LIPA | TAAR1 1380/4885KDM4E 2445/4885MAPK1 3442/4885 |
| US-20060172978-A1 | Method of neutralising organoboronates with acids | LIPC, CYP8B1, SCD | TAAR1 700/4885KDM4E 2721/4885MAPK1 3452/4885 |
| US-20100022646-A1 | METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS | LIPC, CYP8B1, SCD | TAAR1 700/4885KDM4E 2721/4885MAPK1 3452/4885 |
| US-20110281949-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE AND MODULATING TRANSIENT RECEPTOR POTENTIAL CHANNELS | TRPV1, TRPM8, TRPC3 | TAAR1 319/4885KDM4E 3348/4885MAPK1 1666/4885 |
| US-20090061031-A1 | Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus | LPL, ADIPOR2, EBP | TAAR1 4529/4885KDM4E 4389/4885MAPK1 4215/4885 |
| US-12059003-B2 | Antimicrobial compositions effective against bacteria and fungus | XDH, MPO, XPA | TAAR1 1329/4885KDM4E 4244/4885MAPK1 1766/4885 |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | TAAR1 3562/4885KDM4E 4615/4885MAPK1 1563/4885 |
| US-12558399-B2 | Isocyclosporin A for topical treatment of ocular diseases | MALT1, ICOS, IDO2 | TAAR1 3278/4885KDM4E 1510/4885MAPK1 1337/4885 |
| US-20180147206-A1 | ACTIVATION OF NEURONAL STORE-OPERATED CALCIUM ENTRY PATHWAY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CAMK2A, CAMK2G, CAMK2B | TAAR1 2071/4885KDM4E 3364/4885MAPK1 1172/4885 |
| US-20240349724-A1 | ANTIMICROBIAL COMPOSITIONS EFFECTIVE AGAINST BACTERIA AND FUNGUS | XDH, MPO, XPA | TAAR1 1329/4885KDM4E 4244/4885MAPK1 1766/4885 |
| US-20090275649-A1 | Compositions And Methods For Identifying Modulars Of TRPV2 | TRPV2, TRPV1, TRPV3 | TAAR1 1227/4885KDM4E 4054/4885MAPK1 2415/4885 |
| US-20140296141-A1 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus | LPL, ADIPOR2, EBP | TAAR1 4529/4885KDM4E 4389/4885MAPK1 4215/4885 |
| US-20260124270-A1 | ISOCYCLOSPORIN A FOR TOPICAL TREATMENT OF OCULAR DISEASES | TPMT, INMT, MTOR | TAAR1 2416/4885KDM4E 1806/4885MAPK1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.